Bozek Andrzej, Starczewska-Dymek Liwia, Jarzab Jerzy
Clinical Department of Internal Disease, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland.
Medical Center LA Dymek, Strzelce Opolskie, Poland.
Ann Allergy Asthma Immunol. 2017 Jul;119(1):77-82. doi: 10.1016/j.anai.2017.05.012.
The prolonged effect of allergen immunotherapy is unknown, especially in older patients.
To analyze the 3-year effect of sublingual allergen-specific immunotherapy (SLIT) to house dust mites in elderly patients with allergic rhinitis.
Forty-seven elderly patients (65.78 ± 4.89 years old) underwent SLIT to house dust mites and were monitored for 3 years and compared with a placebo group. SLIT was performed with the use of oral Staloral 300 SR Der p and Der f 50/50% extract (Stallergens Greer, London, United Kingdom) or placebo. Symptoms and medication score, represented by the average adjusted symptom score (AAdSS), serum level of immunoglobulin (Ig) G4 to Dermatophagoides pteronyssinus, Dermatophagoides farinae, Der p 1, and Der p 2, and quality of life, were assessed immediately after SLIT and 3 years later.
The AAdSS was significantly decreased after SLIT, and the level remained low during the 3 years after SLIT compared with placebo. Serum-specific IgG4 against D pteronyssinus, D farinae, Der p 1, and Der p 2 increased during the SLIT trial in the study group. For the 3 years of observation after SLIT, there were no significant changes of specific IgG4 levels against the analyzed allergens compared with results just after SLIT. Quality of life based on the Rhinoconjunctivitis Quality of Life Questionnaire score was significantly decreased in patients who received SLIT, from 1.48 (95% confidence interval 1.33-1.79) to 0.98 (95% confidence interval 0.67-1.07; P < .05) compared with 0.94 (95% confidence interval 0.55-1.04) 3 years after SLIT.
The prolonged positive effect after SLIT to house dust mites was observed in elderly patients with allergic rhinitis. Further trials are needed to confirm this effect.
ClinicalTrials.gov Identifier: NCT01605760.
变应原免疫疗法的长期效果尚不清楚,尤其是在老年患者中。
分析舌下尘螨变应原特异性免疫疗法(SLIT)对老年变应性鼻炎患者的3年疗效。
47例老年患者(65.78±4.89岁)接受舌下尘螨免疫疗法,并进行3年监测,与安慰剂组进行比较。使用口服Staloral 300 SR Der p和Der f 50/50%提取物(Stallergens Greer,英国伦敦)或安慰剂进行SLIT。在SLIT后及3年后,评估症状和药物评分(以平均调整症状评分(AAdSS)表示)、针对粉尘螨、屋尘螨、Der p 1和Der p 2的免疫球蛋白(Ig)G4血清水平以及生活质量。
SLIT后AAdSS显著降低,与安慰剂相比,SLIT后3年内该水平一直较低。在研究组的SLIT试验期间,针对粉尘螨、屋尘螨、Der p 1和Der p 2的血清特异性IgG4升高。在SLIT后的3年观察期内,与SLIT刚结束时的结果相比,针对所分析变应原的特异性IgG4水平无显著变化。接受SLIT的患者基于变应性鼻结膜炎生活质量问卷评分的生活质量显著降低,从1.48(95%置信区间1.33 - 1.79)降至0.98(95%置信区间0.67 - 1.07;P <.05),而SLIT后3年为0.94(95%置信区间0.55 - 1.04)。
在老年变应性鼻炎患者中观察到舌下尘螨免疫疗法后的长期积极效果。需要进一步试验来证实这一效果。
ClinicalTrials.gov标识符:NCT01605760。